Summary
To understand the genetic variation underlying atrial fibrillation (AF), the most common cardiac arrhythmia, we performed a genome-wide association study (GWAS) of > 1 million people, including 60,620 AF cases and 970,216 controls. We identified 163 independent risk variants at 111 loci and prioritized 165 candidate genes likely to be involved in AF. Many of the identified risk variants fall near genes where more deleterious mutations have been reported to cause serious heart defects in humans or mice (MYH6, NKX2-5, PITX2, TBC1D32, TBX5), 1, 2 or near genes important for striated muscle function and integrity (e.g. MYH7, PKP2, SSPN, SGCA). Experiments in rabbits with heart failure and left atrial dilation identified a heterogeneous distributed molecular switch from MYH6 to MYH7 in the left atrium, which resulted in contractile and functional heterogeneity and may predispose to initiation and maintenance of atrial arrhythmia.
Results
We tested the association between 34,740,186 genetic variants (minor allele frequency [MAF] > 2.5x10 Table 2 , and Supplementary Table 3 ). Based on approximate stepwise conditional analyses, 3 we identified 52 additional genetic risk variants within the 111 loci that demonstrated genome-wide statistically significant association with AF (Supplementary Table 4 ) that were independent of the locus index variant (LD r 2 < 0.05). We applied the widely used GWAS P-value significance threshold of P-value < 5x10 -8 . Some have suggested to use a more stringent threshold of 5x10 -9 when testing millions of imputed markers. 4 If we had applied this threshold, we would still identify 94 loci, 63 of which have not been previously reported (Supplementary Table 2 ).
Of the 35 loci previously reported for AF (Supplementary Table 3) , we identified genome-wide significant association (P-value < 5x10 -8 ) at 31 (89%) after excluding results from the previously published AFGen Consortium, which has published the majority loci reported to date (Supplementary Table 5 ). 5 The 4 loci not captured comprised 3 loci discovered in East Asian populations (KCNIP1, NEBL, and CUX2) and 1 locus (PLEC) for which we did not have data on the previously reported missense variant. 6 To further test the validity of our findings, we performed a heterogeneity test for the 111 index variants across the 6 contributing studies. Of the 111 index variants, only 2 index variants showed evidence for heterogeneity in the effect size across the 6 contributing studies (P-value < 0.05/111 = Table 2 ). Both of these index variants represent loci that have previously been established as associated with AF across multiple studies (near PRRX1, PITX2) (Supplementary Table 3 ).
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These findings demonstrate a high external validity of our results.
To understand the biology underlying the 111 AF-associated loci, we employed a number of approaches, including 'Data-driven Expression Prioritized Integration for Complex Traits' (DEPICT) 7 to identify cell types and tissues in which genes at AF-associated variants are likely to be preferentially expressed. Based on 37,427 human microarray expression samples from 209 different tissues and cell types, we observed a statistically significant enrichment for atrial (P-value = 2.4x10 -5 ), atrial appendage (P-value = 2.8x10 -5 ), heart (P-value = 5.2x10 -5 ), and ventricular tissues (P-value = 1.1x10 -4 ) (Figure 2a and Supplementary Table 6) . We further applied DEPICT to detect gene sets that were enriched for genes at AF-associated loci. Of the 14,461 gene sets we tested, 889 were enriched (false discovery rate [FDR] < 0.05) for genes at AF-associated loci (Figure 2b and Supplementary Table 7) . The highlighted gene sets in general point to biological processes related to cardiac development and morphology along with structural remodeling of the myocardium. These findings are in line with recent reports which have linked AF with rare coding variants in the sarcomere genes MYH6 and MYL4 and in the multidomain cyto-skeletal linking protein PLEC along with more common coding variants in TTN, essential for the passive elasticity of heart and skeletal muscle. 8, 9, 6, 10 Although we could identify protein-altering variants at n = 21 loci, comprising either the index variant (n = 2 loci) or a variant in high linkage disequilibrium (LD) (r 2 ) with the index variant (n = 19 loci; Table 9 ). This suggests that some loci are important in transcriptional regulation in the adult heart, in development of the fetal heart, or both.
Supplementary
To further enhance the biological understanding of the AF-associated loci, we identified candidate functional genes. There were 3,072 genes or transcripts for which the transcription region overlapped (see Methods) at least one variant in the 111 loci. We prioritized biological candidate genes which: i) harbored a protein-altering variant that was in high LD (r 2 > 0.80; Supplementary Table 8) or was itself the locus index variant; ii) expression levels were associated and colocalized with AFassociated variants (P-value < 1.14 x 10 -9 in GTEx consortium data); 13 iii) were highlighted by DEPICT (FDR < 0.05); or iv) were nearest to the index variant in a locus. Using these criteria, we prioritized 165 target genes (Supplementary Table 2 To identify tissues in which the 165 prioritized candidate genes showed enhanced expression, we used 'Tissue Specific Expression Analysis' (TSEA) 14 and found enrichment in heart (P-value = 5x10 -12 ), muscle (P-value = 1x10 -9 ) and blood vessel tissues (P-value = 2x10 -9 ). To assess the empirical significance of these results, we performed 1,000 permutations of the same number of genes selected: i) randomly from the genome and ii) subsets of the 3,072 genes within the 111 AF loci. We determined that the observed P-values were substantially more significant than expected by chance (Figure 3 ). These findings support that the genes we prioritized are strong candidates for being involved in AF. Figure 3) .
Sixty variants were associated with at least one ECG parameter when we controlled for a false discovery rate of 0.05 at the variant level, 39 of which were novel AF variants including many with substantial ECG effects, such as the variants near NACA, THRB, CAMK2D, NKX2-5, and CDKN1A.
For the locus around index variant rs422068 on chromosome 14, our approach prioritized MYH6
and MYH7 as the most likely functional genes (Supplementary Table 2 ). MYH6 encodes myosin heavy chain alpha (a-MyHC), a major component of the thick filaments of the contractile apparatus in adult atria, and hence important for atrial contraction. 18 MYH7 encodes b-MyHC, a slower acting isoform, 19 and is mainly expressed in the ventricles of the human heart. It has been established that MYH6 and MYH7 are regulated in an inverse manner, and that in heart failure and other cardiac disorders in humans, β-MHC is upregulated, whereas α-MHC is downregulated, resulting in diminution of cardiac performance. 20 Whether these changes occur also in the atria has not previously been addressed.
To explore potential mechanisms of MYH6 and MYH7 in AF, we developed an ischemic heart failure model for AF in rabbits. Ischemia was produced by chronic ligation of the left circumflex artery (LCX) during thoracotomy with subsequent development of ischemic heart failure (> 4 weeks post operatively) and profound left atrial dilation. We found that MYH7 expression was only detectable in the heart failure remodeled left atrium (Figure 4) . The control left atrium did not express detectable levels of MYH7 and exclusively expressed MYH6. More importantly, in the dilated left atrium, MYH7 expression was heterogeneously distributed and thus resulted in contractile heterogeneity, which may have predisposed hearts to develop long-lasting AF, particularly when intra-atrial pressure was increased to 10cm H 2 O. Control hearts did not develop long-lasting AF until intra-atrial pressure was increased to 30cm H 2 O. (Figure 4, Supplementary Figure 4) . Altogether, this experiment demonstrated that a MYH6 to MYH7 switch in the atria may accompany or predispose to atrial fibrillation, and that the expression of both the faster and slower myosin heavy chain forms may predispose to arrhythmia through contractile heterogeneity.
Next, we investigated whether any of the 165 biological candidate genes that we identified could potentially represent a novel drug target for already developed drugs or drugs undergoing development by querying the Drug-Gene Interaction Database. 21 We found one or more potential drug or substance-interactions for 39 of the 165 prioritized genes, totaling 523 drugs. Of these, 77 drugs targeting 16 genes are already known to be able to control or trigger AF or other cardiac arrhythmias (Supplementary Table 12 ). Gene-drug interactions worth highlighting include the interaction between MYH6 and MYH7 and omecamtiv mecarbil and the interaction between KCNH2 and rottlerin.
Omecamtiv mecarbil is a cardiac-specific myosin activator which is currently being tested for treatment of heart failure 22 . Rottlerin, a natural product isolated from the tree Mallotus philippensis, has been shown to increase cardiac contractile performance and coronary perfusion through mitochondrial BK Ca++ channel activation in rat hearts. 23 Whether these or the other highlighted drugs can impact AF needs further evaluation but the findings can be used as a foundation for directing future functional experiments and clinical trials.
Finally, we constructed polygenic risk scores using weighted effect estimates generated from the deCODE sample (13,471 AF cases vs. 358,161 controls). We tested the performance of the deCODEbased weighted polygenic risk score against prevalent AF in the Norwegian HUNT study (6,337 cases vs.
61,607 controls) using a variety of different thresholds of association P-values and LD pruning thresholds. We observed the highest area under the receiver operating curve using genotype dosages for markers with a P-value < 5x10 -5 that were pruned using an LD r 2 -threshold of 0.8 (n = 725 risk markers; AUC = 57.7%, Supplementary Figure 5) . We used this optimized polygenic risk score to test for association with 1,494 International Classification of Diseases (ICD) code-defined disease groups in UK Biobank participants of white British ancestry. 24 In addition to a strong association with AF (P-value = 7x10 -374 ), we found association to 33 mainly cardiovascular conditions (P-value < 0.05/1,494 = 3.3x10 -5 ), including palpitations, mitral valve disorders, hypertension, heart failure, ischemic heart disease, and stroke (Supplementary Table 13 and Supplementary Figure 6) . However, when participants diagnosed with any type of cardiac arrhythmia (n = 24,681) were excluded from the analyses to avoid assessment bias, the AF risk score was not associated with any ICD disease group (P-value > 3.3x10 -5 ). This suggests that the score is specific for AF or cardiac arrhythmia and that the additional associations that we identified were mediated through AF, either as a result of a more thorough clinical examination (e.g valvular disease) or because AF is a likely intermediate step towards the disease (e.g. stroke).
In summary, we substantially increased the number of genome-wide significant risk variants for AF through a large GWAS meta-analysis. Based on pathway and functional enrichment analyses along with prioritization of functional candidate genes we anticipate that many AF risk variants act in the developing heart or impact AF via structural remodeling of the myocardium in the form of an 'atrial cardiomyopathy' 25 as a response to atrial stress in the adult heart. This finding needs confirmation but provides a strong foundation for directing future functional experiments to better understand the biology underlying AF.
Methods

Discovery cohorts
More details on some cohorts are provided in the Supplementary Appendix. HUNT: The Nord-Trøndelag Health Study (HUNT) is a population-based health survey conducted in the county of Nord-Trøndelag, Norway, since 1984. 26 We used a combination of hospital, out-patient, and emergency room discharge diagnoses (ICD-9 and ICD-10) to identify 6,337 AF cases and 61,607 AF-free controls with genotype data. 35 In brief, study participants were genotyped using two very similar genotyping arrays (Applied Biosystems™ UK BiLEVE Axiom™ Array and UK BioBank Axiom™ Array) designed specifically for the UK Biobank. Phasing and imputation was done by the UK Biobank analyses team based on the HRC reference panel and the UK10K haplotype resource. 35 We restricted our analyses to HRC-imputed markers only as there have been reports of incorrect estimates for non-HRC markers in the first 500,000 people release from UK Biobank. We performed testing for association with AF in people of white British ancestry using a generalized mixed model including covariates birth year, sex, genotype batch, and principal PC 1-4 as implemented SAIGE.
DeCODE
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Meta-analysis
We included all markers that were available for analyses in any of the 6 contributing studies. For the DiscoverEHR that applied the BOLT-LMM mixed model, we obtained an approximation of the allelic log-OR and corresponding variance from the linear model as described previously. 36 Following this, we performed a meta-analyses using the inverse variance method implemented in the software package METAL (http://genome.sph.umich.edu/wiki/METAL_Documentation). 37 When estimating the crosscohort allele frequencies, we only included participating studies where individuals were sampled independent of AF status (HUNT, deCODE, MGI, DiscoverEHR, UK Biobank). This was done to avoid sampling bias. Heterogeneity tests were performed as implemented in METAL.
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Definition of independent loci
Independent loci were defined as genetic markers > 1Mb and > 0.25 cM apart in physical and genomic distance, respectively, with at least 1 genetic variant associated with AF at a genome-wide significance threshold of P-value < 5 x 10 -8 . The lower loci boarders were defined as the genome-wide statistically significant marker within the loci with the lowest genomic position minus 1Mb. The upper loci boarders were defined as the genome-wide statistically significant marker within the loci with the highest genomic position plus 1Mb.
Linkage disequilibrium (LD) estimation
We used 5,000 unrelated individuals that were randomly sampled among the HUNT Study participants to calculate calculated LD r 2 using the software PLINK1.9 (https://www.cog-genomics.org/plink/1.9).
Approximate, stepwise conditional analyses
To identify independent risk variants within the identified AF-associated loci, we used the COJO-GCTA software (http://cnsgenomics.com/software/gcta/) to performed approximate, stepwise conditional analyses based on summary statistics from the meta-analyses and a LD-matrix obtained from 5,000 unrelated individuals randomly sampled from the HUNT Study. 3 Only variants with MAF > 0.01 were included in the analyses and variants were only considered truly independent if they were not in LD (r 2 < 0.05) with the locus index variant and any of the other independent risk variants.
Identifying candidate functional genes using DEPICT
We employed DEPICT (https://data.broadinstitute.org/mpg/depict/) to identify 1) the most likely causal gene at associated loci, 2) reconstituted gene sets enriched for AF loci, and 3) tissues and cell types in which genes that form associated loci are highly expressed. 7 DEPICT uses gene expression data derived from a panel of 77,840 mRNA expression arrays 38 together with 14,461 existing gene sets defined based on molecular pathways derived from experimentally verified protein-protein interactions, 39 genotypephenotype relationships from the Mouse Genetics Initiative, 40 Reactome pathways, 41 KEGG pathways, 42 and Gene Ontology (GO) terms. 43 Based on similarities across the microarray expression data, DEPICT reconstitutes the 14,461 existing gene sets by assigning each gene in the genome a likelihood of membership in each gene set. Using these precomputed gene sets and a set of trait-associated loci, DEPICT quantifies whether any of the 14,461 reconstituted gene sets are significantly enriched for genes in the associated loci and prioritizes genes that share predicted functions with genes from the other associated loci more often than expected by chance. Additionally, DEPICT uses a set of 37,427 human mRNA microarrays to identify tissues and cell types in which genes from associated loci are highly expressed (all genes residing within a LD of r 2 > 0.5 from index variant).
We ran DEPICT using all AF-associated index variants and variants identified through stepwise conditional analyses. For the gene sets significantly enriched for AF-associated loci (P-value < 1 x 10 -6 , FDR <0.05), we computed a weighted pairwise similarity based on the number of overlapping genes for genes with a Z score < 4.75 (corresponding to P-value < 1 X 10 -6 ) for being part of the gene set. For gene sets with no genes with a Z score < 4.75, we included the 3 most significant genes as done previously.
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GREGOR
We tested for enrichment of index variants with functional domains using the software GREGOR (http://csg.sph.umich.edu/GREGOR/). 12 This method tests for an increase in the number of AFassociated index variants, or their LD proxies, overlapping with the regulatory feature more often than expected by chance by comparing to permuted control sets where the index variant is matched for frequency, number of LD proxies and distance to the nearest gene. We use a saddle-point approximation to estimate the P-value by comparing to the distribution of permuted statistics. 12 We ran GREGOR using all AF-associated index variants along with variants identified through stepwise conditional analyses.
Identification of expression quantitative trait loci (eQTLs) using GTEx data
We performed eQTL look-up using the GTEx database (http://gtexportal.org) 13 version 6p, which holds cis-eQTLs expression data of up to 190 million single nucleotide variants across 44 tissues, by searching for all AF-associated loci index variants, all independent risk variants identified from the stepwise conditional analyses, and any variants in strong LD (r 2 > 0.80) with these variants using an eQTL significance threshold of P < 1.14 x 10 -9 (5 x 10 -8 / 44 tissues). For all statistically significant genes, we queried all markers in the GTEx database that affected the expression of the affected genes and tested if the eQTLs markers colocalized with the GWAS signal as described previously.
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Ischemic heart failure model of atrial fibrillation susceptibility
Ischemic heart failure was modeled using a previously described rabbit model of left circumflex artery ligation. In this model, the left atrium progressively dilates following the ischemic insult as heart failure develops. Figure 4a shows images of Langendorff perfused hearts of control and heart failure (HF) animals highlighting the overt dilation of the left atrium in HF. With equivalent left atrial pressure (10 cm H 2 O) AF was induced in each condition with high frequency burst pacing as shown in the ECG traces and done before. 46 Protein expression analysis were performed using western blot.
Tissue Specific Expression Analysis (TSEA)
The TSEA analyses were performed using the R software pSI package (http://genetics.wustl.edu/jdlab/psi_package/). 14 For the calculations, pre-defined pSI values provided by the pSI package creators were used. To get null distributions for the P-values for the prioritized genes, we performed two sets of permutations; randomly selected from the entire human genome and randomly selected from the associated loci (also matching the number of genes picked in each of the loci). In both scenarios one thousand permutations were done. were extracted from the database for analysis. The Philips PageWriter Trim III QT interval measurement algorithm has been previously described and shown to fulfill industrial ECG measurement accuracy standards. 47 The Philips PR interval and QRS complex measurements have been shown to fulfill industrial accuracy standards. 48 We tested 111 genome-wide significant and replicated AF variants for association with 123 ECG measurements using a linear mixed effects model implemented in the Bolt software package, 33 treating the ECG measurement as the response and the genotype as the covariate. All measures except heart rate and QT corrected are presented for all 12 ECG leads. For this analysis, we used 289,297 sinus rhythm ECGs (heart rate 50-100 beats per minute) from 62,974 individuals who have not been diagnosed with AF according to our databases. This was done to assess the effect of the AF variants on ECG measures and cardiac electrical function in the absence of AF. Individuals with pacemakers were also excluded. The ECG measurements were adjusted for sex, year of birth, and age at measurement and were subsequently quantile standardized to have a normal distribution. For individuals with multiple ECG measurements, the mean standardized value was used. We assume that the quantitative measurements follow a normal distribution with a mean that depends linearly on the expected allele at the variant and a variance-covariance matrix proportional to the kinship matrix. 49 Since 123 traits were tested, the Benjamini-Hochberg FDR procedure controlling the FDR at 0.05 at each marker was used to account for multiple testing.
Electrocardiogram data
Polygenic risk score
Using dosage-weighted effect estimates obtained from the Iceland-based deCODE population, we constructed 20 GWAS-based polygenic risk cores by combining genetic markers across different GWAS P-value thresholds (P-value < 5 x 10 -4 , P-value < 5 x 10 -5 , P-value < 5 x 10 -6 , P-value < 5 x 10 -7 , P-value < 5
x 10 -8 ) and LD cut-offs (r 2 < 0.2, r 2 < 0.4, r 2 < 0.6, r 2 < 0.8). We evaluated the performance of each of the 20 polygenic risk scores against AUC for predicting prevalent AF in the Norwegian-specific HUNT Study using a logistic regression.
Phenome-wide association analyses
We used a previously published scheme to defined disease-specific binary phenotypes by combining hospital ICD-9 codes into hierarchical PheCodes, each representing a more or less specific disease group. 50 ICD-10 codes were mapped to PheCodes using a combination of available maps through the Unified Medical Language System(https://www.nlm.nih.gov/research/umls/) and other sources, string matching, and manual review. Study participants were labeled a PheCode if they had one or more of the PheCode-specific ICD codes. Cases were all study participants with the PheCode of interest and controls were all study participants without the PheCode of interest or any related PheCodes. Gender checks were performed, so PheCodes specific for one gender could not mistakenly be assigned to the other gender. The association between the optimized polygenic risk score and each of the defined phenotypes where tested using a logistic regression adjusted for sex and birth year.
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